Publication | Closed Access

First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours

MedicinePharmacologyAdvanced Solid TumoursPharmacotherapyAnti-cancer AgentCancer TreatmentFirst ReportOncologyRadiation OncologyJapanese Patients